Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527414 | 0.80 | SCN10A (0.45) | TRPV1KDM4EALDH1A1MAPTPKM | |
| SCHEMBL13677029 | 0.72 | OGA (0.65) | OGAKDM4EALDH1A1PKM | |
| SCHEMBL29445427 | 0.70 | GRIN2D (0.50) | HRH4HRH3TRPV1KDM4EALDH1A1 | |
| SCHEMBL22587519 | 0.70 | GRIN2D (0.50) | HRH4HRH3TRPV1KDM4EALDH1A1 | |
| SCHEMBL2978442 | 0.70 | MAPT (0.47) | HRH3KDM4EALDH1A1MAPTPKM | |
| SCHEMBL25803202 | 0.69 | HRH3 (0.59) | HRH3 | |
| SCHEMBL14117522 | 0.69 | HTR2A (0.36) | TRPV1 | |
| SCHEMBL21725515 | 0.69 | TRPV1 (0.42) | TRPV1KDM4EALDH1A1MAPT | |
| SCHEMBL25809682 | 0.69 | OGA (0.60) | HRH3OGAKDM4EALDH1A1PKM | |
| SCHEMBL25510874 | 0.68 | HSD17B10 (0.42) | TRPV1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005073193-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HRH4 45/4885HRH3 114/4885OGA 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.